CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...